MindRank AI Appointed as Council Member of 'TangXinXiang' Industrial Innovation Alliance, Empowering New Drug R&D with Artificial Intelligence

At the conference, Niu Zhangming, founder and CEO of MindRank, delivered a keynote speech titled "AI Empowering Drug Discovery: From Finding a Needle in a Haystack to Following a Roadmap," sharing how artificial intelligence can systematically enhance the efficiency of drug discovery and drive the transformation of innovative drug development from traditional models to intelligent approaches.

After joining the alliance, MindRank will receive more support in policy alignment and resource integration, helping the company accelerate technological innovation and the transformation of research achievements. At the same time, the company will also bring cutting-edge technologies and innovative experiences in the AI pharmaceutical field to the alliance. Currently, the GLP-1RA oral small molecule new drug designed with the assistance of MindRank's self-developed industrial-grade one-stop AI R&D platform has completed Phase IIb clinical trials with excellent data, and it is about to enter Phase III clinical trials.

MindRank will take the alliance as a fulcrum to deepen innovative collaboration with all sectors of the industry in the future, accelerate the transformation of AI R&D advantages into actual clinical value, and contribute to making the Qiantang District a highland of influential biopharmaceutical industry innovation.